Eurabiolife is a consulting company dedicated to business development activities in the biotechnological and pharmaceutical fields in China.
Level 14, China World Office 1
N°1 Jian Guo Wai avenue
Beijing 100004, P.R. China
Tel: +86 10 6535 0213
Fax: +86 10 6535 0199
HLA-G Technologies SA is a French biotechnology company focused on the development and commercialization of naturally occurring HLA-G proteins.
Its mission is to market innovative products for unmet medical needs, particularly in transplantation, autoimmune diseases including psoriasis, and cancer, and to conclude technological partnerships to support product development programs.
Initially described in pregnant women, at the level of the foeto-maternal barrier, HLA-G is naturally expressed during pregnancy. HLA-G molecules inhibit the main defence mechanisms of the maternal immune system, thus leading to immune tolerance between mother and child.
HLA-G technologies will use the immune tolerance properties of HLA-G molecules to develop treatments in pathologies where an immune tolerance is expected as in transplantation or in autoimmune diseases (psoriasis, rheumatoid arthritis etc.). HLA-G molecules inhibit also the proliferation of malignant cell lines in hematologic blood cancers and have an inhibitory effect on B lymphocyte differentiation.
Inversely, in solid cancers, the development of anti-HLA-G monoclonal antibodies should block detrimental immunosuppressive effects related to the abnormal presence of HLA-G molecules on malignant cells. This is the case of a large number of cancers.
Contact person: Mr Jacques-François Martin